Results 291 to 300 of about 269,130 (350)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Monovalent mannose‐glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and ...
María Elena Angarita‐Planchez   +6 more
wiley   +1 more source

Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS‐Induced Colitis by Regulating AMPK Signalling

open access: yesCell Proliferation, EarlyView.
Luteolin alleviates DSS‐induced ulcerative colitis in mice by targeting the NLRP3 inflammasome, as it shows no effect in NLRP3‐/‐ mice. It inhibits NLRP3 activation and IL‐1β secretion in macrophages by reducing ROS, mtROS and calcium levels via AMPK binding and signalling. Metabolomic changes suggest lipid metabolism involvement. Luteolin represents a
Lianxiang Luo   +8 more
wiley   +1 more source

AMSC‐sEVs Ameliorated Crohn's Disease by Inhibiting Macrophage‐Myofibroblast Transition Through the Delivery of MFGE8

open access: yesCell Proliferation, EarlyView.
Our study demonstrated that TGF‐β1 activated MAPK signalling pathway and promoted the MMT and secretion of CCL17 under CD‐associated intestinal inflammatory conditions. AMSC‐sEVs can deliver MFGE8, which inhibits MMT and CCL17‐mediated Treg recruitment by suppressing the MAPK signalling pathway, thereby alleviating intestinal fibrosis.
Minghao Xie   +6 more
wiley   +1 more source

The proteomic differences and expression of fatty acid‐binding protein 6 (FABP6) associated with gastrointestinal injury in horses with oral administration of a clinical dose of phenylbutazone

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Phenylbutazone (PBZ) can potentially induce gastrointestinal ulceration, and early detection of PBZ‐induced gastroenteropathy will be useful for the diagnosis, treatment, and prevention of PBZ toxicity. Objectives To identify putative proteins associated with equine gastric ulcer syndrome after clinical dose (4.4 mg/kg ...
Ruethaiwan Vinijkumthorn   +6 more
wiley   +1 more source

Chronic hepatitis in horses with persistent equine hepacivirus infection

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Equine hepacivirus (EqHV) is closely related to hepatitis C virus (HCV), which causes persistent infection and chronic hepatitis in people. Information on persistent EqHV infection and hepatitis is limited. Objectives To report 19 cases of chronic hepatitis and persistent EqHV infection.
Mason C. Jager   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy